WHO ICTRP trial
Quercetin as an antiviral agent against Coronavirus infection: Double blind…
PACTR202406512501178 · Pan African Clinical Trials Registry (PACTR) · Not Recruiting
Key facts
| Trial ID | PACTR202406512501178 |
|---|---|
| Public title | Quercetin as an antiviral agent against Coronavirus infection: Double blind clinical trial |
| Scientific title | Quercetin supplementation and covid 19 evolution: a randomized clinical trial in hospitalized patients |
| Primary sponsor | HDC laboratory |
| Registry | Pan African Clinical Trials Registry (PACTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase-3 |
| Countries | Tunisia;Tunisia |
| Conditions | Respiratory; Respiratory |
| Registration date | Apr 3, 2024 |
| Target size | 244 |
| Registry page | pactr.samrc.ac.za |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: